Chamber
Meeting of the Parliament 20 February 2013
20 Feb 2013 · S4 · Meeting of the Parliament
Item of business
New Medicines
The member has made his point.
Many of the quotes used by Mark McDonald are from papers that were issued at the commencement of the cancer drugs fund in the expectation that something better would follow in Scotland in the interim. However, we have not made progress in the interim. In consequence, some 25,000 people in England have had access to treatments for cancer that have not been available in Scotland. By calculation, some 2,500 people in Scotland have been denied access to life-saving treatments.
Oncologists made clear the consequences to the Health and Sport Committee during its inquiry. They said:
“If the situation remains with regard to poorer access to new medicines, it will negatively impact on this aspiration, due to a drift in oncologists from within Scotland conducting less innovative research. In addition, due to Scotland in many situations no longer treating patients with the standard of care used in other parts of the world, Scotland may not be able to take the lead or take part in global clinical research studies”.
We cannot afford to allow Scotland to be marginalised in the future development and treatment of cancer.
I pay tribute to the Cabinet Secretary for Health and Wellbeing. He has commissioned the Routledge and Swainson reviews and, in consequence of the Health and Sport Committee inquiry, he is, to some extent, seeking to escape from the electric policy chair—if I can call it that—of previous Government policy.
We recognise that, from next year, potential value-based pricing will change the emphasis and allow an assessment of the progress of a drug to be calculated. It will put the boot on the other foot and place the emphasis on the pharmaceutical companies to make these drugs available.
Nanette Milne will talk about Tina McGeever and Mike Gray. I would like, by illustration, to talk about Ken Macintosh, who hosted a dinner on behalf of Mascot Melanoma Action Support Scotland. At the event we heard from Girish Gupta, NHS Lanarkshire, and from Tim Crook, consultant medical oncologist at the University of Dundee. We also heard from Paula McIntyre, whose husband, Scott, died last year. He was given access to ipilimumab through a clinical trial—the drug gave him six additional months of life.
In Joan McAlpine’s article in last week’s Daily Record, she summarised that as:
“New drugs are often of negligible benefit—they prolong life for just a few weeks or months—and only then in particular patients.”
Many of the quotes used by Mark McDonald are from papers that were issued at the commencement of the cancer drugs fund in the expectation that something better would follow in Scotland in the interim. However, we have not made progress in the interim. In consequence, some 25,000 people in England have had access to treatments for cancer that have not been available in Scotland. By calculation, some 2,500 people in Scotland have been denied access to life-saving treatments.
Oncologists made clear the consequences to the Health and Sport Committee during its inquiry. They said:
“If the situation remains with regard to poorer access to new medicines, it will negatively impact on this aspiration, due to a drift in oncologists from within Scotland conducting less innovative research. In addition, due to Scotland in many situations no longer treating patients with the standard of care used in other parts of the world, Scotland may not be able to take the lead or take part in global clinical research studies”.
We cannot afford to allow Scotland to be marginalised in the future development and treatment of cancer.
I pay tribute to the Cabinet Secretary for Health and Wellbeing. He has commissioned the Routledge and Swainson reviews and, in consequence of the Health and Sport Committee inquiry, he is, to some extent, seeking to escape from the electric policy chair—if I can call it that—of previous Government policy.
We recognise that, from next year, potential value-based pricing will change the emphasis and allow an assessment of the progress of a drug to be calculated. It will put the boot on the other foot and place the emphasis on the pharmaceutical companies to make these drugs available.
Nanette Milne will talk about Tina McGeever and Mike Gray. I would like, by illustration, to talk about Ken Macintosh, who hosted a dinner on behalf of Mascot Melanoma Action Support Scotland. At the event we heard from Girish Gupta, NHS Lanarkshire, and from Tim Crook, consultant medical oncologist at the University of Dundee. We also heard from Paula McIntyre, whose husband, Scott, died last year. He was given access to ipilimumab through a clinical trial—the drug gave him six additional months of life.
In Joan McAlpine’s article in last week’s Daily Record, she summarised that as:
“New drugs are often of negligible benefit—they prolong life for just a few weeks or months—and only then in particular patients.”
In the same item of business
The Deputy Presiding Officer (John Scott)
Con
The next item of business is a debate on motion S4M-05664, in the name of Jackson Carlaw, on health. 15:55
Jackson Carlaw (West Scotland) (Con)
Con
The Conservatives have framed the motion with a view to making qualitative progress on the subject of cancer in this afternoon’s debate. In that spirit, we w...
Mark McDonald (North East Scotland) (SNP)
SNP
Will the member take an intervention?
Jackson Carlaw
Con
I will in due course.It is not a choice between detection and making drugs available—those are two halves of the approach that the Parliament should ensure i...
Mark McDonald
SNP
I know that Mr Carlaw was making a fleeting political point, but I will quote to him what Breakthrough Cancer Scotland said:“Breakthrough would suggest that ...
Jackson Carlaw
Con
The member has made his point. Many of the quotes used by Mark McDonald are from papers that were issued at the commencement of the cancer drugs fund in the ...
Joan McAlpine (South Scotland) (SNP)
SNP
Will the member take an intervention?
Jackson Carlaw
Con
No—I want to make the point.I am not someone who gets overly emotional in politics—I have been around long enough to know that the hard knocks come and they ...
The Cabinet Secretary for Health and Wellbeing (Alex Neil)
SNP
This is a difficult and very sensitive subject. I think that we all recognise that making decisions about which medicines to provide for national health serv...
Jim Eadie (Edinburgh Southern) (SNP)
SNP
Does the cabinet secretary recognise that public trust and confidence go to the heart of the debate, and that the public have a right to expect that if their...
Alex Neil
SNP
I will deal with some of those points later in my speech.Thousands of medicines in various doses and formulations are available to clinicians in the UK. In S...
Jackie Baillie (Dumbarton) (Lab)
Lab
I welcome the opportunity to debate access to new medicines in the NHS and the tone of the speeches made by Jackson Carlaw and the cabinet secretary. I also ...
The Deputy Presiding Officer (Elaine Smith)
Lab
You are in your last minute.
Jackie Baillie
Lab
Fourteen different ways of doing things is no longer acceptable.Let me turn to the orphan drugs fund. That is very welcome, but it must not just be a stickin...
The Deputy Presiding Officer
Lab
The debate is extremely tight, and we have already lost a member from it. I ask members to take only their four minutes.16:18
Aileen McLeod (South Scotland) (SNP)
SNP
I welcome the opportunity to debate a very serious and sensitive issue, particularly as a member of the Health and Sport Committee, as the issue forms part o...
Jackson Carlaw
Con
I understand the point that the member is making, but she has just referred to the £21 million that has been made available for the rare conditions medicine ...
Aileen McLeod
SNP
I speak as somebody who has worn both hats: one as a policy maker and one as a cancer victim and survivor. I am therefore acutely aware of how cancer suffere...
Duncan McNeil (Greenock and Inverclyde) (Lab)
Lab
I am sure that we will hear a lot in the debate about the National Institute for Health and Clinical Excellence, the Scottish Medicines Consortium, individua...
Joan McAlpine
SNP
I think that the member was referring to my article in the Daily Record and I thank him for taking an intervention from me, which Mr Carlaw did not have the ...
The Deputy Presiding Officer
Lab
Please be brief.
Joan McAlpine
SNP
Does the member agree that there is an issue to do with pharmaceutical companies holding the health service to ransom—
Duncan McNeil
Lab
The member will speak in the debate. I hope that I will be given additional time.
The Deputy Presiding Officer
Lab
I am afraid that this is a very short debate.
Duncan McNeil
Lab
I accept that the premise of Ms McAlpine’s article was that politicians should not be involved in the process at all. However, we set the parameters and we p...
The Deputy Presiding Officer
Lab
You must conclude, Mr McNeil.
Duncan McNeil
Lab
That is why the cabinet secretary instigated a review of the process. It matters that we lost precious time. That time was not as precious for us as it was f...
The Deputy Presiding Officer
Lab
I advise members that we might have to lose another speaker from the debate. Members must take interventions in their own time.16:26
Bob Doris (Glasgow) (SNP)
SNP
I welcome the debate, although I cannot accept the Conservative motion. I will explain to Jackson Carlaw why that is the case. Mr Carlaw will not share this ...
Dr Richard Simpson (Mid Scotland and Fife) (Lab)
Lab
That is the clinician’s decision.